Savior LLC Makes New $44,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Share on StockTwits

Savior LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, Holdings Channel.com reports. The fund acquired 134 shares of the medical research company’s stock, valued at approximately $44,000.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Thermo Fisher Scientific by 1.4% in the second quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock valued at $8,118,461,000 after acquiring an additional 392,227 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Thermo Fisher Scientific by 0.6% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,683,947 shares of the medical research company’s stock valued at $490,483,000 after purchasing an additional 10,168 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Thermo Fisher Scientific by 3.3% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,203,808 shares of the medical research company’s stock worth $350,633,000 after buying an additional 37,955 shares in the last quarter. California Public Employees Retirement System raised its holdings in shares of Thermo Fisher Scientific by 28.2% during the 3rd quarter. California Public Employees Retirement System now owns 893,555 shares of the medical research company’s stock worth $260,266,000 after buying an additional 196,657 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Thermo Fisher Scientific by 1.0% in the third quarter. California State Teachers Retirement System now owns 721,001 shares of the medical research company’s stock valued at $210,006,000 after buying an additional 6,824 shares in the last quarter. Hedge funds and other institutional investors own 88.31% of the company’s stock.

Shares of NYSE TMO opened at $335.38 on Friday. The company has a market capitalization of $136.36 billion, a PE ratio of 37.68, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a twelve month low of $235.90 and a twelve month high of $342.26. The firm has a fifty day simple moving average of $326.72 and a 200 day simple moving average of $299.56.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating the Zacks’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The business had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.19 billion. During the same quarter in the prior year, the firm posted $2.62 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 12.33 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, November 8th that allows the company to repurchase $2.50 million in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th were given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.23%. The ex-dividend date was Monday, December 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

A number of equities analysts have recently commented on the stock. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, January 6th. They set a “buy” rating and a $380.00 price target on the stock. Credit Suisse Group initiated coverage on Thermo Fisher Scientific in a report on Wednesday. They issued a “neutral” rating and a $341.00 price objective for the company. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird upped their price target on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $325.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Portfolio Manager

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.